-
Pyrotech Biotechnology’s PTT-936 Gets US FDA Clinical Trial Approval
•
Pyrotech (Beijing) Biotechnology Co., Ltd, a China-based biotech firm, has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its in-house developed innate immune agonist, PTT-936. The specific targeted indication for this trial remains undisclosed. Mechanism of Action and Preclinical Success PTT-936…
-
Pyrotech (Beijing) Biotechnology Secures $97.37 Million in Series A Financing
•
China-based biotech firm Pyrotech (Beijing) Biotechnology Co., Ltd announced the successful completion of a CNY 700 million (USD 97.37 million) Series A financing round last week. The round was spearheaded by SDIC Venture Capital, with China Venture Capital Fund as a co-leader. New participants in this funding round included China…
